SavedAdd your journal

Journals / Annals of Medical Research / 2020 / Cilt: 27 - Sayı: 4

Botulinum Neurotoxin-A therapy in patients with refractory overactive bladder

Osman BARUT
Sefa RESİM
Pages
1163–1167
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

After the treatment, hematuria developed in 3 female and 2 male patients and urinary tract infections developed in 4 females and 2 male patients.Conclusion: BonTA injection significantly improves the daily urinary frequency, incontinence, and quality of life scores in patients with OAB.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AbstractAim: The aim of this study was to evaluate the clinical efficacy and safety of intravesical botulinum neurotoxin-A injection in patients with refractory overactive bladder to conservative treatment and anti-muscarinic drugs.Material and Methods: The data of 62 patients, who received botulinum neurotoxin-A (BonTA) injection (100 U) for overactive bladder (OAB) between 2015 and 2019, were reviewed retrospectively.
📊
Key Findings & Data:For 55 patients included into the study, the urinary frequency and urgency, the number of incontinence and nocturia episodes, the maximum flow rate (Qmax), the post-void residual volume (PVR), and the Urinary Incontinence Quality of Life (I-QoL) scores were evaluated before the treatment and at the third month after the treatment.Results: The comparison of the pre-treatment and posttreatment 3rd-month follow-up data revealed a statistically significant decrease in the urinary frequency and urgency, and the number of incontinence and nocturia episodes (p 0.05).
💡
Conclusion & Impact:After the treatment, hematuria developed in 3 female and 2 male patients and urinary tract infections developed in 4 females and 2 male patients.Conclusion: BonTA injection significantly improves the daily urinary frequency, incontinence, and quality of life scores in patients with OAB.
🔬Design:Review & Systematic Survey
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

AbstractAim: The aim of this study was to evaluate the clinical efficacy and safety of intravesical botulinum neurotoxin-A injection in patients with refractory overactive bladder to conservative treatment and anti-muscarinic drugs.Material and Methods: The data of 62 patients, who received botulinum neurotoxin-A (BonTA) injection (100 U) for overactive bladder (OAB) between 2015 and 2019, were reviewed retrospectively. For 55 patients included into the study, the urinary frequency and urgency, the number of incontinence and nocturia episodes, the maximum flow rate (Qmax), the post-void residual volume (PVR), and the Urinary Incontinence Quality of Life (I-QoL) scores were evaluated before the treatment and at the third month after the treatment.Results: The comparison of the pre-treatment and posttreatment 3rd-month follow-up data revealed a statistically significant decrease in the urinary frequency and urgency, and the number of incontinence and nocturia episodes (p 0.05). The mean I-QoL score increased significantly in the posttreatment 3rd month compared to the pre-treatment scores (43.62 ± 11.2 and 75.2 ± 12.6, p = 0.001, respectively). After the treatment, hematuria developed in 3 female and 2 male patients and urinary tract infections developed in 4 females and 2 male patients.Conclusion: BonTA injection significantly improves the daily urinary frequency, incontinence, and quality of life scores in patients with OAB.

🔖

Cite This Article

BARUT, O., RESİM, S. (2022). Botulinum Neurotoxin-A therapy in patients with refractory overactive bladder. Annals of Medical Research, Cilt: 27 - Sayı: 4, 1163–1167. https://ajindex.com/articles/446476

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: Report from the standardisation subcommittee of the International Continence Society. Neurourol Urodyn 2002:21;167-78
  2. Abrams P, Kelleher CJ, Kerr LA, et al. Overactive bladder significantly affects quality of life. Am J Manag Care 2000;6:580
  3. Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology 2002;60:7
  4. Homma Y, Yamaguchi O, Hayashi K. Epidemiologic survey of lower urinary tract symptoms in Japan. Urology 2006;68:560
  5. Colman S, Chapple C, Nitti V, et al. Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder. Urology 2008;72:803-7
  6. Astellas Pharma US, Inc. Myrbetriq (mirabegron) extended release tablets. US prescribing information. 2012. Available from: http://www. accessdata.fda. gov/drugsatfda_docs/label/ 2012/202611s000lbl.pdf [Accessed 12 December 2013] 7. Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 2015;193:1572
  7. Phé V, de Wachter S, Rouprêt M, et al. How to define a refractory idiopathic overactive bladder? Neurourol Urodyn 2015;34:2-11
  8. Groen J, Pannek J, Castro Diaz D, et al. Summary of European Association of Urology (EAU) Guidelines on NeuroUrology. Eur Urol 2016;69:324-33
  9. Lucas MG, Bedretdinova D, Berghmans LC, et al. EAU 2015 guidelines on urinary incontinence. Available at: http://uroweb.org/ wp-content/uploads/EAUGuidelines-Urinary-Incontinence-2015.pdf
  10. Van Ermengem E. Ueber einen neuen anaeroben Bacillus and seine Beziehungen zum Botulisms.Ztsch Hyg Infekt 1897:26;1
  11. Giannantoni A, Di Stasi SM, Nardicchi V, et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 2006:175;2341-4
  12. Roosen A, Data SN, Chowdhury RA, et al. Suburothelial myofibroblasts in the human overactive bladder and the effect of botulinum neurotoxin type A treatment. Eur Urol 2009:55;1440-9
  13. Apostolidis A, Dasgupta P, Denys P, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 2009;55:100-20
  14. Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta(3)-Adrenoceptor Agonist, i